Coppersmith Capital Management (5.8% stake) wants Alere (ALR -0.9%) to consider selling its drug...


Coppersmith Capital Management (5.8% stake) wants Alere (ALR -0.9%) to consider selling its drug testing business for ~$2.5B in order to pay down debt, according to Reuters, citing people familiar with the matter. This wouldn't be Coppersmith's first call for asset sales: the investment firm has said publicly that ALR should either sell or shutter its health management business.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs